GT Biopharma is trading 6.96% up at $0.31 in pre-market on September 2, 2026, based on the supplied pre-market data, with no clear company-specific catalyst identified.
- Searches found no clearly dated September 1–2 announcement, earnings release, financing, clinical update, or regulatory catalyst; the latest identified filing was August 14.
- Broader markets were weaker, so macro sentiment does not clearly explain the opposite-direction move. Activity and volume details were unavailable.